Analyst Bullish on Cogent (COGT) Amid Anticipated Drug Approval

Cogent Biosciences Inc. (NASDAQ:COGT) is likely one of the 15 shares with the largest hedge fund momentum, after gaining 25 hedge fund holders through the fourth quarter of 2025. On February 18, Piper Sandler analysts raised their worth goal on Cogent Biosciences Inc. (NASDAQ:COGT) t0 $52 from $39. In accordance with these analysts, who maintained an Chubby ranking on Cogent Biosciences Inc. (NASDAQ:COGT), their $13 enhance on the value goal is justified by the corporate’s shift towards regulatory approvals and industrial readiness following fourth-quarter 2025 outcomes.

Piper Sandler famous that Cogent Biosciences Inc. (NASDAQ:COGT) submitted a New Drug Software (NDA) for bezuclastinib in non-advanced systemic mastocytosis, with acceptance anticipated this month. The drug is positioned for potential approval and launch within the second half of 2026. The corporate additionally plans to submit an NDA for second-line gastrointestinal stromal tumors in April and a sophisticated systemic mastocytosis NDA within the first half of 2026. Given these developments, the corporate’s focus now turns to execution because it strikes towards commercialization, in keeping with the analysts.

Cogent Biosciences Inc. (NASDAQ:COGT) is a biotechnology firm that develops precision therapies for genetically outlined ailments.

Whereas we acknowledge the potential of COGT as an funding, we consider sure AI shares provide larger upside potential and carry much less draw back danger. When you’re on the lookout for an especially undervalued AI inventory that additionally stands to profit considerably from Trump-era tariffs and the onshoring development, see our free report on the greatest short-term AI inventory.

READ NEXT: 13 Sizzling Shares to Purchase with the Highest Upside Potential and 10 Greatest Excessive-Upside Supplies Shares to Purchase

Disclosure: None. Observe Insider Monkey on Google Information.